P/B
2,2
Ainos
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
$7.1M
Market Cap • 10/15/2026
1984
(42 years)
Founded
1996
(30 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
7,1M
EV
19,5M
EV/Revenue
0
EV/EBITDA
-2,2
EV/EBIT
-1,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-26,7%
Total Yield
-26,7%
Payout
0%
Retained Earnings
-74,6M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0,5%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
1,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
46,9%
CAGR Net Income 5Y
47,7%
CAGR EPS 5Y
-14,2%
CAGR OCF 5Y
52,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,1
Quick Ratio
0,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!